UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials

The oncologist (Dayton, Ohio), 2019-01, Vol.24 (1), p.96-102

2019

Volltextzugriff (PDF)

Claims-based analysis of treatment practices of patients with metastatic gastroenteropancreatic neuroendocrine tumors (mGEP-NET) in the USA

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e16286-e16286

2024

Volltextzugriff (PDF)

Causes of death following neuroendocrine tumors diagnosis: A United States population-based analysis

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.630-630

2020

Volltextzugriff (PDF)

Disparities in overall survival (OS) outcomes based on treating facility volume in pancreatic neuroendocrine tumors

Journal of clinical oncology, 2022-10, Vol.40 (28_suppl), p.150-150

2022

Volltextzugriff (PDF)

Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.TPS602-TPS602

2024

Volltextzugriff (PDF)

Integration of molecular cancer classification and NGS to identify patients with metastatic cancer eligible for BRAF inhibitors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e15118-e15118

2022

Volltextzugriff (PDF)

Meta-analysis of prognostic biomarkers for pancreatic neuroendocrine tumors (PNETs)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e15688-e15688

2019

Volltextzugriff (PDF)

Chromogranin A as surveillance biomarker in patients with carcinoids: CASPAR

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16242-e16242

2023

Volltextzugriff (PDF)

Clinical outcomes and molecular characteristics of patients with pancreatic acinar cell carcinoma

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.688-688

2024

Volltextzugriff (PDF)

Assessment of hematological toxicity in patients with advanced neuroendocrine tumors and extensive/innumerable bone metastases undergoing lutetium-177 DOTATATE treatment

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.592-592

2024

Volltextzugriff (PDF)

Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.370-370

2021

Volltextzugriff (PDF)

Molecular and clinical characteristics of patients with KRAS mutated pancreatic ductal adenocarcinoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16259-e16259

2023

Volltextzugriff (PDF)

Osteoclast-like giant cell tumors of the pancreas: Clinical characteristics, genetic testing, and treatment modalities

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e16752-e16752

2020

Volltextzugriff (PDF)

Anorectal neuroendocrine carcinoma (NEC): Patient characteristics and treatment outcomes

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e16702-e16702

2020

Volltextzugriff (PDF)

Trends in the incidence and survival outcomes in patients with lung neuroendocrine neoplasms in the United States

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e19120-e19120

2020

Volltextzugriff (PDF)

Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS660-TPS660

2023

Volltextzugriff (PDF)

Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with pembrolizumab, in patients with neuroendocrine carcinoma

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS657-TPS657

2023

Volltextzugriff (PDF)

Efficacy of pembrolizumab as first-line therapy in patients with mismatch repair–deficient metastatic colorectal cancer in relation to the metastatic site

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.57-57

2023

Volltextzugriff (PDF)

Incidence and survival patterns of pancreatic neuroendocrine tumors over the last two decades: A SEER database analysis

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.629-629

2020

Volltextzugriff (PDF)

A multicenter analysis of treatment and outcomes in neuroendocrine carcinoma of the uterine cervix (NCUC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e17518-e17518

2021

Volltextzugriff (PDF)

Enrichment of somatic mosaic states involving DNA damage response and repair genes in patients treated with 177 Lutetium

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.3020-3020

2024

Volltextzugriff (PDF)

Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.55-55

2024

Volltextzugriff (PDF)

Validation of lymphocyte to monocyte ratio in resected small bowel adenocarcinoma as a predictor of survival

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e15799-e15799

2019

Volltextzugriff (PDF)

Clinicopathological features and treatment patterns of patients with cancer of unknown primary site (CUP): Mayo Clinic experience

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18803-e18803

2023

Volltextzugriff (PDF)

Genomic landscape of cancer of unknown primary site (CUP): Mayo Clinic experience

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18807-e18807

2023

Volltextzugriff (PDF)

1 – 25 von 81

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(74)

Publikationsform

Artikel
(81)

Sprache

Englisch
(81)

Erscheinungsjahr

n.n

Thema

Adolescent
(1)
Adult
(1)
Aged
(1)
Aged, 80 And Over
(1)
Clinical Oncology
(1)
Clinical Trials
(1)
Clinical Trials As Topic
(1)
Comorbidities
(1)
Comorbidity - Trends
(1)
Hiv Infection
(1)
Humans
(1)
Investigational Drugs
(1)
Life Sciences & Biomedicine
(1)
Middle Aged
(1)
New Drug Development And Clinical Pharmacology
(1)
Oncology
(1)
Patient Selection
(1)
Science & Technology
(1)
Young Adult
(1)

14 weitere anzeigen...

Weniger anzeigen...

Kollektion

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials

Claims-based analysis of treatment practices of patients with metastatic gastroenteropancreatic neuroendocrine tumors (mGEP-NET) in the USA

Causes of death following neuroendocrine tumors diagnosis: A United States population-based analysis

Disparities in overall survival (OS) outcomes based on treating facility volume in pancreatic neuroendocrine tumors

Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma

Integration of molecular cancer classification and NGS to identify patients with metastatic cancer eligible for BRAF inhibitors

Meta-analysis of prognostic biomarkers for pancreatic neuroendocrine tumors (PNETs)

Chromogranin A as surveillance biomarker in patients with carcinoids: CASPAR

Clinical outcomes and molecular characteristics of patients with pancreatic acinar cell carcinoma

Assessment of hematological toxicity in patients with advanced neuroendocrine tumors and extensive/innumerable bone metastases undergoing lutetium-177 DOTATATE treatment

Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms

Molecular and clinical characteristics of patients with KRAS mutated pancreatic ductal adenocarcinoma

Osteoclast-like giant cell tumors of the pancreas: Clinical characteristics, genetic testing, and treatment modalities

Anorectal neuroendocrine carcinoma (NEC): Patient characteristics and treatment outcomes

Trends in the incidence and survival outcomes in patients with lung neuroendocrine neoplasms in the United States

Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial

Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with pembrolizumab, in patients with neuroendocrine carcinoma

Efficacy of pembrolizumab as first-line therapy in patients with mismatch repair–deficient metastatic colorectal cancer in relation to the metastatic site

Incidence and survival patterns of pancreatic neuroendocrine tumors over the last two decades: A SEER database analysis

A multicenter analysis of treatment and outcomes in neuroendocrine carcinoma of the uterine cervix (NCUC)

Enrichment of somatic mosaic states involving DNA damage response and repair genes in patients treated with 177 Lutetium

Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting

Validation of lymphocyte to monocyte ratio in resected small bowel adenocarcinoma as a predictor of survival

Clinicopathological features and treatment patterns of patients with cancer of unknown primary site (CUP): Mayo Clinic experience

Genomic landscape of cancer of unknown primary site (CUP): Mayo Clinic experience

Suchergebnisse filtern